Verity Asset Management Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,938 shares of the medical research company’s stock, valued at approximately $318,000.
A number of other large investors have also recently modified their holdings of AMGN. Camelot Portfolios LLC acquired a new stake in Amgen during the first quarter worth approximately $1,429,000. Telos Capital Management Inc. lifted its position in Amgen by 1.6% during the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after acquiring an additional 227 shares during the last quarter. Cadence Bank NA lifted its position in Amgen by 6.2% during the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after acquiring an additional 197 shares during the last quarter. Palladium Partners LLC raised its position in shares of Amgen by 1.9% in the first quarter. Palladium Partners LLC now owns 112,042 shares of the medical research company’s stock valued at $18,382,000 after buying an additional 2,079 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its position in shares of Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock valued at $6,377,000 after buying an additional 16,080 shares in the last quarter. Institutional investors and hedge funds own 78.09% of the company’s stock.
AMGN has been the subject of a number of analyst reports. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, June 13th. Mizuho reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Sunday, July 9th. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. Finally, Cann reissued a “buy” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $186.14.
Amgen Inc. (AMGN) opened at 185.76 on Friday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The firm has a market cap of $135.54 billion, a price-to-earnings ratio of 16.92 and a beta of 1.35. The stock’s 50 day moving average is $175.99 and its 200 day moving average is $169.31.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $2.84 EPS. On average, analysts predict that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.